Innovative Cellular Therapeutics Holdings Ltd 4
4 · Lyell Immunopharma, Inc. · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
Lyell (LYEL) 10% Owner Transfers 76,000 Shares as Broker Commission
What Happened Innovative Cellular Therapeutics Holdings Ltd, a reported 10% owner of Lyell Immunopharma (LYEL), transferred 76,000 shares of Lyell common stock on June 29, 2026. The shares were transferred for no cash consideration (reported price $0.00) as a broker commission, so there were no proceeds to the reporting person. After the transfer, the reporting person beneficially owned approximately 2,857,500 shares (2,933,500 before the transfer).
Key Details
- Transaction date: 2026-06-29; Form 4 filed 2026-07-01.
- Transaction type/code: Other disposition (code J) — transfer of shares for no cash consideration.
- Shares transferred: 76,000 at $0.00; total reported value $0.
- Shares owned after transaction: ~2,857,500 common shares.
- Footnotes: F1 — shares transferred to Wuxiong, Inc. as broker commission related to an Upfront Payment under a License Agreement (dated Nov 6, 2025). F2 — ownership numbers reflect the pre-transfer and post-transfer counts.
- No late filing indication in the form (filed July 1, 2026).
Context This was an institutional transfer (10% owner) of stock as a broker commission tied to a license agreement, not an open-market sale or purchase by an executive. Transfers made to pay broker fees or similar obligations are routine and do not necessarily signal management sentiment about the company. No cash changed hands in this transaction.
Insider Transaction Report
- Other
Common Stock
[F1][F2]2026-06-29−76,000→ 2,857,500 total
Footnotes (2)
- [F1]Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the Upfront Payment (as such term is defined in the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.
- [F2]Reflects 2,933,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 76,000 shares transferred.